-
1
-
-
84907087561
-
Zile MR, Investigators P-H and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure
-
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K. Zile MR, Investigators P-H and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.
-
(2014)
N Engl J Med
, vol.371
, pp. 993-1004
-
-
McMurray, J.J.1
Packer, M.2
Desai, A.S.3
Gong, J.4
Lefkowitz, M.P.5
Rizkala, A.R.6
Rouleau, J.L.7
Shi, V.C.8
Solomon, S.D.9
Swedberg, K.10
-
2
-
-
84992053005
-
A test in context: neprilysin: function, inhibition, and biomarker
-
Bayes-Genis A, Barallat J, Richards AM. A test in context: neprilysin: function, inhibition, and biomarker. J Am Coll Cardiol. 2016;68:639–653.
-
(2016)
J Am Coll Cardiol
, vol.68
, pp. 639-653
-
-
Bayes-Genis, A.1
Barallat, J.2
Richards, A.M.3
-
3
-
-
84922822387
-
Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients
-
Bayes-Genis A, Barallat J, Galan A, de Antonio M, Domingo M, Zamora E, Urrutia A, Lupon J. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015;65:657–665.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 657-665
-
-
Bayes-Genis, A.1
Barallat, J.2
Galan, A.3
de Antonio, M.4
Domingo, M.5
Zamora, E.6
Urrutia, A.7
Lupon, J.8
-
4
-
-
84954139643
-
Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction
-
Goliasch G, Pavo N, Zotter-Tufaro C, Kammerlander A, Duca F, Mascherbauer J, Bonderman D. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction. Eur J Heart Fail. 2016;18:89–93.
-
(2016)
Eur J Heart Fail
, vol.18
, pp. 89-93
-
-
Goliasch, G.1
Pavo, N.2
Zotter-Tufaro, C.3
Kammerlander, A.4
Duca, F.5
Mascherbauer, J.6
Bonderman, D.7
-
5
-
-
0037425535
-
Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic
-
Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003;289:194–202.
-
(2003)
JAMA
, vol.289
, pp. 194-202
-
-
Redfield, M.M.1
Jacobsen, S.J.2
Burnett, J.C.3
Mahoney, D.W.4
Bailey, K.R.5
Rodeheffer, R.J.6
-
6
-
-
0037019567
-
Plasma brain natriuretic peptide concentration: impact of age and gender
-
Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–982.
-
(2002)
J Am Coll Cardiol
, vol.40
, pp. 976-982
-
-
Redfield, M.M.1
Rodeheffer, R.J.2
Jacobsen, S.J.3
Mahoney, D.W.4
Bailey, K.R.5
Burnett, J.C.6
-
7
-
-
80052047215
-
Progression of left ventricular diastolic dysfunction and risk of heart failure
-
Kane GC, Karon BL, Mahoney DW, Redfield MM, Roger VL, Burnett JC Jr, Jacobsen SJ, Rodeheffer RJ. Progression of left ventricular diastolic dysfunction and risk of heart failure. JAMA. 2011;306:856–863.
-
(2011)
JAMA
, vol.306
, pp. 856-863
-
-
Kane, G.C.1
Karon, B.L.2
Mahoney, D.W.3
Redfield, M.M.4
Roger, V.L.5
Burnett, J.C.6
Jacobsen, S.J.7
Rodeheffer, R.J.8
-
8
-
-
77951625683
-
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
-
McKie PM, Cataliotti A, Lahr BD, Martin FL, Redfield MM, Bailey KR, Rodeheffer RJ, Burnett JC Jr. The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol. 2010;55:2140–2147.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 2140-2147
-
-
McKie, P.M.1
Cataliotti, A.2
Lahr, B.D.3
Martin, F.L.4
Redfield, M.M.5
Bailey, K.R.6
Rodeheffer, R.J.7
Burnett, J.C.8
-
9
-
-
0030098039
-
History of the rochester epidemiology project
-
Melton LJ III. History of the rochester epidemiology project. Mayo Clin Proc. 1996;71:266–274.
-
(1996)
Mayo Clin Proc
, vol.71
, pp. 266-274
-
-
Melton, L.J.1
-
10
-
-
0022471069
-
Atrial natriuretic peptide elevation in congestive heart failure in the human
-
Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, Opgenorth TJ, Reeder GS. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science. 1986;231:1145–1147.
-
(1986)
Science
, vol.231
, pp. 1145-1147
-
-
Burnett, J.C.1
Kao, P.C.2
Hu, D.C.3
Heser, D.W.4
Heublein, D.5
Granger, J.P.6
Opgenorth, T.J.7
Reeder, G.S.8
-
11
-
-
79960914260
-
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community
-
Cannone V, Boerrigter G, Cataliotti A, Costello-Boerrigter LC, Olson TM, McKie PM, Heublein DM, Lahr BD, Bailey KR, Averna M, Redfield MM, Rodeheffer RJ, Burnett JC Jr. A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. J Am Coll Cardiol. 2011;58:629–636.
-
(2011)
J Am Coll Cardiol
, vol.58
, pp. 629-636
-
-
Cannone, V.1
Boerrigter, G.2
Cataliotti, A.3
Costello-Boerrigter, L.C.4
Olson, T.M.5
McKie, P.M.6
Heublein, D.M.7
Lahr, B.D.8
Bailey, K.R.9
Averna, M.10
Redfield, M.M.11
Rodeheffer, R.J.12
Burnett, J.C.13
-
12
-
-
84937546817
-
Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population
-
Sangaralingham SJ, McKie PM, Ichiki T, Scott CG, Heublein DM, Chen HH, Bailey KR, Redfield MM, Rodeheffer RJ, Burnett JC Jr. Circulating C-type natriuretic peptide and its relationship to cardiovascular disease in the general population. Hypertension. 2015;65:1187–1194.
-
(2015)
Hypertension
, vol.65
, pp. 1187-1194
-
-
Sangaralingham, S.J.1
McKie, P.M.2
Ichiki, T.3
Scott, C.G.4
Heublein, D.M.5
Chen, H.H.6
Bailey, K.R.7
Redfield, M.M.8
Rodeheffer, R.J.9
Burnett, J.C.10
-
13
-
-
0030934595
-
Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition
-
Florkowski CM, Richards AM, Espiner EA, Yandle TG, Sybertz E, Frampton CM. Low-dose brain natriuretic peptide infusion in normal men and the influence of endopeptidase inhibition. Clin Sci (Lond). 1997;92:255–260.
-
(1997)
Clin Sci (Lond)
, vol.92
, pp. 255-260
-
-
Florkowski, C.M.1
Richards, A.M.2
Espiner, E.A.3
Yandle, T.G.4
Sybertz, E.5
Frampton, C.M.6
-
14
-
-
0027254627
-
Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension
-
Richards AM, Crozier IG, Espiner EA, Yandle TG, Nicholls MG. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension. 1993;22:231–236.
-
(1993)
Hypertension
, vol.22
, pp. 231-236
-
-
Richards, A.M.1
Crozier, I.G.2
Espiner, E.A.3
Yandle, T.G.4
Nicholls, M.G.5
-
15
-
-
0027173606
-
Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II
-
Richards AM, Wittert GA, Crozier IG, Espiner EA, Yandle TG, Ikram H, Frampton C. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens. 1993;11:407–416.
-
(1993)
J Hypertens
, vol.11
, pp. 407-416
-
-
Richards, A.M.1
Wittert, G.A.2
Crozier, I.G.3
Espiner, E.A.4
Yandle, T.G.5
Ikram, H.6
Frampton, C.7
-
16
-
-
84867745957
-
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
-
Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ACEI [Angiotensin-Converting—Enzyme Inhibitor]. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012;380:1387–1395.
-
(2012)
Lancet
, vol.380
, pp. 1387-1395
-
-
Solomon, S.D.1
Zile, M.2
Pieske, B.3
Voors, A.4
Shah, A.5
Kraigher-Krainer, E.6
Shi, V.7
Bransford, T.8
Takeuchi, M.9
Gong, J.10
Lefkowitz, M.11
Packer, M.12
McMurray, J.J.13
-
17
-
-
85030722254
-
Neprilysin and recurrent admissions in patients with heart failure
-
Nunez J, Nunez E, Barallat J, Bodi V, Minana G, Pastor MC, Sanchis J, Lupon J, Serum Bayes-Genis A. Neprilysin and recurrent admissions in patients with heart failure. J Am Heart Assoc. 2017; 6:e005712. DOI: 10.1161/JAHA.117.005712.
-
(2017)
J Am Heart Assoc
, vol.6
-
-
Nunez, J.1
Nunez, E.2
Barallat, J.3
Bodi, V.4
Minana, G.5
Pastor, M.C.6
Sanchis, J.7
Lupon, J.8
Serum Bayes-Genis, A.9
-
18
-
-
84939441219
-
Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study
-
Bayes-Genis A, Barallat J, Pascual-Figal D, Nunez J, Minana G, Sanchez-Mas J, Galan A, Sanchis J, Zamora E, Perez-Martinez MT, Lupon J. Prognostic value and kinetics of soluble neprilysin in acute heart failure: a pilot study. JACC Heart Fail. 2015;3:641–644.
-
(2015)
JACC Heart Fail
, vol.3
, pp. 641-644
-
-
Bayes-Genis, A.1
Barallat, J.2
Pascual-Figal, D.3
Nunez, J.4
Minana, G.5
Sanchez-Mas, J.6
Galan, A.7
Sanchis, J.8
Zamora, E.9
Perez-Martinez, M.T.10
Lupon, J.11
-
19
-
-
84978160778
-
Serum neprilysin and recurrent hospitalizations after acute heart failure
-
Nunez J, Nunez E, Minana G, Carratala A, Sanchis J, Lupon J, Barallat J, Pastor MC, Pascual-Figal D, Bayes-Genis A. Serum neprilysin and recurrent hospitalizations after acute heart failure. Int J Cardiol. 2016;220:742–744.
-
(2016)
Int J Cardiol
, vol.220
, pp. 742-744
-
-
Nunez, J.1
Nunez, E.2
Minana, G.3
Carratala, A.4
Sanchis, J.5
Lupon, J.6
Barallat, J.7
Pastor, M.C.8
Pascual-Figal, D.9
Bayes-Genis, A.10
-
20
-
-
79955759374
-
Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum
-
discussion 2014
-
Borlaug BA, Redfield MM. Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum. Circulation. 2011;123:2006–2013; discussion 2014.
-
(2011)
Circulation
, vol.123
, pp. 2006-2013
-
-
Borlaug, B.A.1
Redfield, M.M.2
-
21
-
-
79956194650
-
Natriuretic peptide metabolism, clearance and degradation
-
Potter LR. Natriuretic peptide metabolism, clearance and degradation. FEBS J. 2011;278:1808–1817.
-
(2011)
FEBS J
, vol.278
, pp. 1808-1817
-
-
Potter, L.R.1
-
22
-
-
0028096121
-
Clearance mechanisms of atrial and brain natriuretic peptides in rats
-
Hashimoto Y, Nakao K, Hama N, Imura H, Mori S, Yamaguchi M, Yasuhara M, Hori R. Clearance mechanisms of atrial and brain natriuretic peptides in rats. Pharm Res. 1994;11:60–64.
-
(1994)
Pharm Res
, vol.11
, pp. 60-64
-
-
Hashimoto, Y.1
Nakao, K.2
Hama, N.3
Imura, H.4
Mori, S.5
Yamaguchi, M.6
Yasuhara, M.7
Hori, R.8
-
23
-
-
84939424765
-
Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure
-
Vodovar N, Seronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Cohen-Solal A, Richards AM, Launay JM, Mebazaa A, Network G. Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure. JACC Heart Fail. 2015;3:629–636.
-
(2015)
JACC Heart Fail
, vol.3
, pp. 629-636
-
-
Vodovar, N.1
Seronde, M.F.2
Laribi, S.3
Gayat, E.4
Lassus, J.5
Januzzi, J.L.6
Boukef, R.7
Nouira, S.8
Manivet, P.9
Samuel, J.L.10
Logeart, D.11
Cohen-Solal, A.12
Richards, A.M.13
Launay, J.M.14
Mebazaa, A.15
Network, G.16
-
24
-
-
84924243546
-
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
-
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile M, Andersen K, Arango JL, Arnold JM, Belohlavek J, Bohm M, Boytsov S, Burgess LJ, Cabrera W, Calvo C, Chen CH, Dukat A, Duarte YC, Erglis A, Fu M, Gomez E, Gonzalez-Medina A, Hagege AA, Huang J, Katova T, Kiatchoosakun S, Kim KS, Kozan O, Llamas EB, Martinez F, Merkely B, Mendoza I, Mosterd A, Negrusz-Kawecka M, Peuhkurinen K, Ramires FJ, Refsgaard J, Rosenthal A, Senni M, Sibulo AS Jr, Silva-Cardoso J, Squire JB, Starling RC, Teerlink JR, Vanhaecke J, Vinereanu D, Wong RC; Investigators P-H and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.
-
(2015)
Circulation
, vol.131
, pp. 54-61
-
-
Packer, M.1
McMurray, J.J.2
Desai, A.S.3
Gong, J.4
Lefkowitz, M.P.5
Rizkala, A.R.6
Rouleau, J.L.7
Shi, V.C.8
Solomon, S.D.9
Swedberg, K.10
Zile, M.11
Andersen, K.12
Arango, J.L.13
Arnold, J.M.14
Belohlavek, J.15
Bohm, M.16
Boytsov, S.17
Burgess, L.J.18
Cabrera, W.19
Calvo, C.20
Chen, C.H.21
Dukat, A.22
Duarte, Y.C.23
Erglis, A.24
Fu, M.25
Gomez, E.26
Gonzalez-Medina, A.27
Hagege, A.A.28
Huang, J.29
Katova, T.30
Kiatchoosakun, S.31
Kim, K.S.32
Kozan, O.33
Llamas, E.B.34
Martinez, F.35
Merkely, B.36
Mendoza, I.37
Mosterd, A.38
Negrusz-Kawecka, M.39
Peuhkurinen, K.40
Ramires, F.J.41
Refsgaard, J.42
Rosenthal, A.43
Senni, M.44
Sibulo, A.S.45
Silva-Cardoso, J.46
Squire, J.B.47
Starling, R.C.48
Teerlink, J.R.49
Vanhaecke, J.50
Vinereanu, D.51
Wong, R.C.52
more..
-
25
-
-
84865527834
-
Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction
-
Anjan VY, Loftus TM, Burke MA, Akhter N, Fonarow GC, Gheorghiade M, Shah SJ. Prevalence, clinical phenotype, and outcomes associated with normal B-type natriuretic peptide levels in heart failure with preserved ejection fraction. Am J Cardiol. 2012;110:870–876.
-
(2012)
Am J Cardiol
, vol.110
, pp. 870-876
-
-
Anjan, V.Y.1
Loftus, T.M.2
Burke, M.A.3
Akhter, N.4
Fonarow, G.C.5
Gheorghiade, M.6
Shah, S.J.7
-
26
-
-
85050153568
-
A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction
-
Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. Circulation. 2018;138:861–870.
-
(2018)
Circulation
, vol.138
, pp. 861-870
-
-
Reddy, Y.N.V.1
Carter, R.E.2
Obokata, M.3
Redfield, M.M.4
Borlaug, B.A.5
-
27
-
-
84875766051
-
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
-
van Veldhuisen DJ, Linssen GC, Jaarsma T, van Gilst WH, Hoes AW, Tijssen JG, Paulus WJ, Voors AA, Hillege HL. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498–1506.
-
(2013)
J Am Coll Cardiol
, vol.61
, pp. 1498-1506
-
-
van Veldhuisen, D.J.1
Linssen, G.C.2
Jaarsma, T.3
van Gilst, W.H.4
Hoes, A.W.5
Tijssen, J.G.6
Paulus, W.J.7
Voors, A.A.8
Hillege, H.L.9
-
28
-
-
85021770915
-
Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction
-
Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136:6–19.
-
(2017)
Circulation
, vol.136
, pp. 6-19
-
-
Obokata, M.1
Reddy, Y.N.V.2
Pislaru, S.V.3
Melenovsky, V.4
Borlaug, B.A.5
-
29
-
-
77957907689
-
Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction
-
Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588–595.
-
(2010)
Circ Heart Fail
, vol.3
, pp. 588-595
-
-
Borlaug, B.A.1
Nishimura, R.A.2
Sorajja, P.3
Lam, C.S.4
Redfield, M.M.5
-
30
-
-
85009423905
-
Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study
-
Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825–838.
-
(2017)
Circulation
, vol.135
, pp. 825-838
-
-
Obokata, M.1
Kane, G.C.2
Reddy, Y.N.3
Olson, T.P.4
Melenovsky, V.5
Borlaug, B.A.6
-
31
-
-
0026093160
-
Modulation of neurogenic inflammation by neutral endopeptidase
-
Nadel JA, Borson DB. Modulation of neurogenic inflammation by neutral endopeptidase. Am Rev Respir Dis. 1991;143:S33–S36.
-
(1991)
Am Rev Respir Dis
, vol.143
, pp. S33-S36
-
-
Nadel, J.A.1
Borson, D.B.2
-
33
-
-
0027475050
-
Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology
-
Roques BP, Noble F, Dauge V, Fournie-Zaluski MC, Beaumont A. Neutral endopeptidase 24.11: structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev. 1993;45:87–146.
-
(1993)
Pharmacol Rev
, vol.45
, pp. 87-146
-
-
Roques, B.P.1
Noble, F.2
Dauge, V.3
Fournie-Zaluski, M.C.4
Beaumont, A.5
-
34
-
-
79551562936
-
Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease
-
Wick MJ, Buesing EJ, Wehling CA, Loomis ZL, Cool CD, Zamora MR, Miller YE, Colgan SP, Hersh LB, Voelkel NF, Dempsey EC. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:330–340.
-
(2011)
Am J Respir Crit Care Med
, vol.183
, pp. 330-340
-
-
Wick, M.J.1
Buesing, E.J.2
Wehling, C.A.3
Loomis, Z.L.4
Cool, C.D.5
Zamora, M.R.6
Miller, Y.E.7
Colgan, S.P.8
Hersh, L.B.9
Voelkel, N.F.10
Dempsey, E.C.11
-
35
-
-
84877265606
-
Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction
-
Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of new-onset heart failure: differences in preserved versus reduced ejection fraction. Circ Heart Fail. 2013;6:279–286.
-
(2013)
Circ Heart Fail
, vol.6
, pp. 279-286
-
-
Ho, J.E.1
Lyass, A.2
Lee, D.S.3
Vasan, R.S.4
Kannel, W.B.5
Larson, M.G.6
Levy, D.7
-
36
-
-
84942933774
-
Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking
-
Ahmed AA, Patel K, Nyaku MA, Kheirbek RE, Bittner V, Fonarow GC, Filippatos GS, Morgan CJ, Aban IB, Mujib M, Desai RV, Allman RM, White M, Deedwania P, Howard G, Bonow RO, Fletcher RD, Aronow WS, Ahmed A. Risk of heart failure and death after prolonged smoking cessation: role of amount and duration of prior smoking. Circ Heart Fail. 2015;8:694–701.
-
(2015)
Circ Heart Fail
, vol.8
, pp. 694-701
-
-
Ahmed, A.A.1
Patel, K.2
Nyaku, M.A.3
Kheirbek, R.E.4
Bittner, V.5
Fonarow, G.C.6
Filippatos, G.S.7
Morgan, C.J.8
Aban, I.B.9
Mujib, M.10
Desai, R.V.11
Allman, R.M.12
White, M.13
Deedwania, P.14
Howard, G.15
Bonow, R.O.16
Fletcher, R.D.17
Aronow, W.S.18
Ahmed, A.19
-
37
-
-
84992088875
-
Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women
-
Eaton CB, Pettinger M, Rossouw J, Martin LW, Foraker R, Quddus A, Liu S, Wampler NS, Hank Wu WC, Manson JE, Margolis K, Johnson KC, Allison M, Corbie-Smith G, Rosamond W, Breathett K, Klein L. Risk factors for incident hospitalized heart failure with preserved versus reduced ejection fraction in a multiracial cohort of postmenopausal women. Circ Heart Fail. 2016;9:e002883.
-
(2016)
Circ Heart Fail
, vol.9
-
-
Eaton, C.B.1
Pettinger, M.2
Rossouw, J.3
Martin, L.W.4
Foraker, R.5
Quddus, A.6
Liu, S.7
Wampler, N.S.8
Hank Wu, W.C.9
Manson, J.E.10
Margolis, K.11
Johnson, K.C.12
Allison, M.13
Corbie-Smith, G.14
Rosamond, W.15
Breathett, K.16
Klein, L.17
-
38
-
-
85053935249
-
Cigarette smoking and incident heart failure: insights from the Jackson heart study
-
Kamimura D, Cain LR, Mentz RJ, White WB, Blaha MJ, DeFilippis AP, Fox ER, Rodriguez CJ, Keith RJ, Benjamin EJ, Butler J, Bhatnagar A, Robertson RM, Winniford MD, Correa A, Hall ME. Cigarette smoking and incident heart failure: insights from the Jackson heart study. Circulation. 2018;137:2572–2582.
-
(2018)
Circulation
, vol.137
, pp. 2572-2582
-
-
Kamimura, D.1
Cain, L.R.2
Mentz, R.J.3
White, W.B.4
Blaha, M.J.5
DeFilippis, A.P.6
Fox, E.R.7
Rodriguez, C.J.8
Keith, R.J.9
Benjamin, E.J.10
Butler, J.11
Bhatnagar, A.12
Robertson, R.M.13
Winniford, M.D.14
Correa, A.15
Hall, M.E.16
-
39
-
-
84988851302
-
Smoking and cardiac structure and function in the elderly: the ARIC Study (Atherosclerosis Risk in Communities)
-
Nadruz W Jr, Claggett B, Goncalves A, Querejeta-Roca G, Fernandes-Silva MM, Shah AM, Cheng S, Tanaka H, Heiss G, Kitzman DW, Solomon SD. Smoking and cardiac structure and function in the elderly: the ARIC Study (Atherosclerosis Risk in Communities). Circ Cardiovasc Imaging. 2016;9:e004950.
-
(2016)
Circ Cardiovasc Imaging
, vol.9
-
-
Nadruz, W.1
Claggett, B.2
Goncalves, A.3
Querejeta-Roca, G.4
Fernandes-Silva, M.M.5
Shah, A.M.6
Cheng, S.7
Tanaka, H.8
Heiss, G.9
Kitzman, D.W.10
Solomon, S.D.11
-
40
-
-
79960347944
-
Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community
-
Lam CS, Lyass A, Kraigher-Krainer E, Massaro JM, Lee DS, Ho JE, Levy D, Redfield MM, Pieske BM, Benjamin EJ, Vasan RS. Cardiac dysfunction and noncardiac dysfunction as precursors of heart failure with reduced and preserved ejection fraction in the community. Circulation. 2011;124:24–30.
-
(2011)
Circulation
, vol.124
, pp. 24-30
-
-
Lam, C.S.1
Lyass, A.2
Kraigher-Krainer, E.3
Massaro, J.M.4
Lee, D.S.5
Ho, J.E.6
Levy, D.7
Redfield, M.M.8
Pieske, B.M.9
Benjamin, E.J.10
Vasan, R.S.11
-
41
-
-
84857857236
-
Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction
-
Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, Wehrens XH, Deswal A. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998–1005.
-
(2012)
J Am Coll Cardiol
, vol.59
, pp. 998-1005
-
-
Ather, S.1
Chan, W.2
Bozkurt, B.3
Aguilar, D.4
Ramasubbu, K.5
Zachariah, A.A.6
Wehrens, X.H.7
Deswal, A.8
-
42
-
-
84971384492
-
Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction
-
Hoeper MM, Meyer K, Rademacher J, Fuge J, Welte T, Olsson KM. Diffusion capacity and mortality in patients with pulmonary hypertension due to heart failure with preserved ejection fraction. JACC Heart Fail. 2016;4:441–449.
-
(2016)
JACC Heart Fail
, vol.4
, pp. 441-449
-
-
Hoeper, M.M.1
Meyer, K.2
Rademacher, J.3
Fuge, J.4
Welte, T.5
Olsson, K.M.6
-
43
-
-
84879748718
-
A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation
-
Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
-
(2013)
J Am Coll Cardiol
, vol.62
, pp. 263-271
-
-
Paulus, W.J.1
Tschope, C.2
-
44
-
-
84953931431
-
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice
-
Suematsu Y, Miura S, Goto M, Matsuo Y, Arimura T, Kuwano T, Imaizumi S, Iwata A, Yahiro E, Saku K. LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice. Eur J Heart Fail. 2016;18:386–393.
-
(2016)
Eur J Heart Fail
, vol.18
, pp. 386-393
-
-
Suematsu, Y.1
Miura, S.2
Goto, M.3
Matsuo, Y.4
Arimura, T.5
Kuwano, T.6
Imaizumi, S.7
Iwata, A.8
Yahiro, E.9
Saku, K.10
-
45
-
-
62549141438
-
Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia
-
Dempsey EC, Wick MJ, Karoor V, Barr EJ, Tallman DW, Wehling CA, Walchak SJ, Laudi S, Le M, Oka M, Majka S, Cool CD, Fagan KA, Klemm DJ, Hersh LB, Gerard NP, Gerard C, Miller YE. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol. 2009;174:782–796.
-
(2009)
Am J Pathol
, vol.174
, pp. 782-796
-
-
Dempsey, E.C.1
Wick, M.J.2
Karoor, V.3
Barr, E.J.4
Tallman, D.W.5
Wehling, C.A.6
Walchak, S.J.7
Laudi, S.8
Le, M.9
Oka, M.10
Majka, S.11
Cool, C.D.12
Fagan, K.A.13
Klemm, D.J.14
Hersh, L.B.15
Gerard, N.P.16
Gerard, C.17
Miller, Y.E.18
-
46
-
-
80053317641
-
Role of neprilysin in airway inflammation induced by diesel exhaust emissions
-
Wong SS, Sun NN, Fastje CD, Witten ML, Lantz RC, Lu B, Sherrill DL, Gerard CJ, Burgess JL; Committee HEIHR. Role of neprilysin in airway inflammation induced by diesel exhaust emissions. Res Rep Health Eff Inst. 2011;159:3–40.
-
(2011)
Res Rep Health Eff Inst
, vol.159
, pp. 3-40
-
-
Wong, S.S.1
Sun, N.N.2
Fastje, C.D.3
Witten, M.L.4
Lantz, R.C.5
Lu, B.6
Sherrill, D.L.7
Gerard, C.J.8
Burgess, J.L.9
-
47
-
-
0030858891
-
Urinary neutral endopeptidase in workers exposed to cadmium: interaction with cigarette smoking
-
Nortier J, Bernard A, Roels H, Deschodt-Lanckman M, Gueuning C, Lauwerys R. Urinary neutral endopeptidase in workers exposed to cadmium: interaction with cigarette smoking. Occup Environ Med. 1997;54:432–436.
-
(1997)
Occup Environ Med
, vol.54
, pp. 432-436
-
-
Nortier, J.1
Bernard, A.2
Roels, H.3
Deschodt-Lanckman, M.4
Gueuning, C.5
Lauwerys, R.6
-
48
-
-
77957228322
-
Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation
-
Pereira NL, Aksoy P, Moon I, Peng Y, Redfield MM, Burnett JC Jr, Wieben ED, Yee VC, Weinshilboum RM. Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. J Mol Cell Cardiol. 2010;49:864–874.
-
(2010)
J Mol Cell Cardiol
, vol.49
, pp. 864-874
-
-
Pereira, N.L.1
Aksoy, P.2
Moon, I.3
Peng, Y.4
Redfield, M.M.5
Burnett, J.C.6
Wieben, E.D.7
Yee, V.C.8
Weinshilboum, R.M.9
-
49
-
-
0026702428
-
Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors
-
Yandle T, Richards M, Smith M, Charles C, Livesey J, Espiner E. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin Chem. 1992;38:1785–1791.
-
(1992)
Clin Chem
, vol.38
, pp. 1785-1791
-
-
Yandle, T.1
Richards, M.2
Smith, M.3
Charles, C.4
Livesey, J.5
Espiner, E.6
-
50
-
-
0025277862
-
Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid
-
Spillantini MG, Sicuteri F, Salmon S, Malfroy B. Characterization of endopeptidase 3.4.24.11 (“enkephalinase”) activity in human plasma and cerebrospinal fluid. Biochem Pharmacol. 1990;39:1353–1356.
-
(1990)
Biochem Pharmacol
, vol.39
, pp. 1353-1356
-
-
Spillantini, M.G.1
Sicuteri, F.2
Salmon, S.3
Malfroy, B.4
-
51
-
-
28444443740
-
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
-
Hawkridge AM, Heublein DM, Bergen HR III, Cataliotti A, Burnett JC Jr, Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA. 2005;102:17442–17447.
-
(2005)
Proc Natl Acad Sci USA
, vol.102
, pp. 17442-17447
-
-
Hawkridge, A.M.1
Heublein, D.M.2
Bergen, H.R.3
Cataliotti, A.4
Burnett, J.C.5
Muddiman, D.C.6
-
52
-
-
79960584348
-
Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure
-
Miller WL, Phelps MA, Wood CM, Schellenberger U, Van Le A, Perichon R, Jaffe AS. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail. 2011;4:355–360.
-
(2011)
Circ Heart Fail
, vol.4
, pp. 355-360
-
-
Miller, W.L.1
Phelps, M.A.2
Wood, C.M.3
Schellenberger, U.4
Van Le, A.5
Perichon, R.6
Jaffe, A.S.7
-
53
-
-
84922777256
-
Unwinding the interaction of natriuretic peptides and neprilysin
-
Jaffe AS. Unwinding the interaction of natriuretic peptides and neprilysin. J Am Coll Cardiol. 2015;65:666–667.
-
(2015)
J Am Coll Cardiol
, vol.65
, pp. 666-667
-
-
Jaffe, A.S.1
|